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The immunoinhibitory receptor T cell immunoglobulin domain and mucin domain-3 (Tim-3) and its ligand,
galectin-9 (Gal-9), are involved in the immune evasion mechanisms for several pathogens causing chronic
infections. However, there is no report concerning the role of Tim-3 in diseases of domestic animals. In this study,
cDNA encoding for bovine Tim-3 and Gal-9 were cloned and sequenced, and their expression and role in immune
reactivation were analyzed in bovine leukemia virus (BLV)-infected cattle. Predicted amino acid sequences of Tim-3
and Gal-9 shared high homologies with human and mouse homologues. Functional domains, including tyrosine
kinase phosphorylation motif in the intracellular domain of Tim-3 were highly conserved among cattle and other
species. Quantitative real-time PCR analysis showed that bovine Tim-3 mRNA is mainly expressed in T cells such as
CD4+ and CD8+ cells, while Gal-9 mRNA is mainly expressed in monocyte and T cells. Tim-3 mRNA expression in
CD4+ and CD8+ cells was upregulated during disease progression of BLV infection. Interestingly, expression levels
for Tim-3 and Gal-9 correlated positively with viral load in infected cattle. Furthermore, Tim-3 expression level
closely correlated with up-regulation of IL-10 in infected cattle. The expression of IFN-γ and IL-2 mRNA was
upregulated when PBMC from BLV-infected cattle were cultured with Cos-7 cells expressing Tim-3 to inhibit the
Tim-3/Gal-9 pathway. Moreover, combined blockade of the Tim-3/Gal-9 and PD-1/PD-L1 pathways significantly
promoted IFN-γ mRNA expression compared with blockade of the PD-1/PD-L1 pathway alone. These results
suggest that Tim-3 is involved in the suppression of T cell function during BLV infection.Introduction
In humans and mice, T cell immunoglobulin domain
and mucin domain-3 (Tim-3), a member of the Tim
family has been identified as a transmembrane protein,
which contains an immunoglobulin and a mucin-like
domain and is expressed on various cells such as CD4
+Th1 cells, cytotoxic T-lymphocytes (CTL), monocytes
and dendritic cells and natural killer cells, and charac-
terized as a negative regulator for immune responses
[1-3]. Tim-3 contains a predicted intracellular tyrosine-
kinase phosphorylation motif, and acts as a functional
receptor that transduces signals through the phosphory-
lated tyrosine residue [3,4]. Galectin-9 (Gal-9), a mem-
ber of the Galectin family (also called S-type lectins) is
secreted by several cells, and has been identified as the
Tim-3 ligand [5]. Gal-9 consists of N- and C-terminal* Correspondence: okazu@vetmed.hokudai.ac.jp
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reproduction in any medium, provided the orcarbohydrate-binding domains, which are connected by
a link peptide, and binds to Tim-3 via a carbohydrate
chain [5-7]. Gal-9-induced intracellular calcium flux,
aggregation, inhibition of cell proliferation and cytokine
production as well as death of T cells are known to be
Tim-3-dependent [5,8,9]. Tim-3 is expressed on acti-
vated T cells, including Th1 CD4+ and CD8+ cells
resulting in selective loss of interferon (IFN)-γ produ-
cing cells and concomitant suppression of cell-mediated
immunity. These observations suggest that the Tim-3
/Gal-9 pathway may have evolved to ensure effective
termination of effector Th1 cells [5].
Recently, several inhibitory receptor molecules in-
cluding the Tim-3/Gal-9 pathway have been closely
associated with immune exhaustion and disease pro-
gression in chronic infectious diseases and tumors [10-
14]. Tim-3 is highly expressed on exhausted T-cells in
lymphocytic choriomeningitis virus (LCMV) [15],
Human Immunodeficiency Virus (HIV) [16], hepatitis Cal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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melanoma [19]. Meanwhile, Gal-9 production from
Kupffer cells is elevated during chronic HCV infection,
and the elevated Gal-9 results in expansion of
CD4+CD25+FoxP3+ regulatory T cells, contraction of
CD4+ effector T cells, and apoptosis of HCV-specific
CTL [20]. Thus, the Tim-3/Gal-9 pathway is one of the
mechanisms in downregulating immune responses dur-
ing chronic disease progression, and a potential target for
novel immunotherapeutic intervention. However, there is
no information available about the role of the Tim-3/Gal-
9 pathway in bovine diseases.
Bovine leukemia virus (BLV), a retrovirus related to
human T-cell leukemia virus type 1 (HTLV-1), causes
enzootic bovine leucosis (EBL). Infection by BLV can re-
main clinically silent, with cattle in an aleukemic (AL)
state, or it can emerge as a persistent lymphocytosis
(PL), characterized by an increased number of B lym-
phocytes, and, more rarely, as B-cell lymphomas in vari-
ous lymph nodes after a long latent period [21]. Recent
work in our laboratory has revealed that inhibitory
receptor molecules play a critical role in immune
exhaustion and disease progression in BLV-infection
[22-24], and blocking the inhibitory pathway in vitro
increases cytokine responses and enhances function
leading to a decrease in the viral load [23]. Therefore,
such an evaluation of inhibitory receptor expression kin-
etics is essential to improve the design of an effective
immunotherapy that can induce cell-mediated immune
responses. In this study, to determine the possible role
of bovine Tim-3 in chronic infectious diseases, we
cloned both bovine Tim-3 and its ligand, Gal-9, and
characterized their expression profiles using quantitative
real-time PCR in cattle infected with BLV.
Materials and methods
Cloning of cDNA encoding for bovine Tim-3 and Gal-9
Bovine peripheral blood mononuclear cells (PBMC) were
purified from heparinized venous blood of Holstein-
Friesian breed maintained at the Graduate School of
Veterinary Medicine, Hokkaido University, by density
gradient centrifugation on Percoll solution (GE Healthcare
UK Ltd., Amersham Place, Little Chalfont, Buckingham-
shire, England). The PBMC were cultivated with 5 μg/mL
Concanavalin A (Con A) (Sigma-Aldrich, St. Louis, MO,
USA) for 12 h at 37°C in 5% CO2. Total RNA was isolated
from cultivated PBMC using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions, and residual DNA was removed from the
RNA samples by treatment with Deoxyribonuclease I
(Invitrogen). cDNA was synthesized from 1 μg of total
RNA with Moloney murine leukemia virus reverse
transcriptase (Takara, Shiga, Japan) and the oligo-dT
primer (0.5 mg/mL) according to the manufacturer’sinstructions. To clone bovine Tim-3 and Gal-9 genes,
specific primers were designed based on the sequences
from Hereford breed cattle reported in the GenBank
database (XM_001077105 and NM_001039177). Tim-3
cDNA was amplified by PCR using specific primers,
5′-AAA CGG CAC CTA AAC AGA GC-3′ and
5′-GAC AAC ACC AAG CCC CTA GA-3′. The cyc-
ling conditions consisted of initial denaturation at 94°C
for 5 min, followed by 40 cycles of 94°C for 30 s, 55–
47°C at the rate of 0.2°C/cycle for 1 min and 72°C for
1 min, and final extension at 72°C for 7 min. Gal-9
cDNA was amplified by PCR using specific primers,
5′-GGG AGA AGT GGC AGT GGC TAC AGA-3′ and
5′-ATC CAG ATA GCA GCA CAG GGC AG-3′. PCR
condition was the same as above except annealing
temperature (60–52°C). The PCR amplicons were
purified by GENECLEAN III Kit (Q-Biogene, Carlsbad,
CA, USA) and cloned into the pGEM-T Easy vector
(Promega, Madison, WI, USA). The purified plasmid
clones were sequenced using CEQ 2000 DNA Analysis
System (Beckman Coulter, Fullerton, CA, USA). The
established sequences were aligned, and an unrooted
neighbor-joining tree was constructed using MEGA
software program version 5.0 [25].
Expression analysis of bovine Tim-3 and Gal-9 mRNA
CD4+, CD8+, CD5+, CD14+ and CD21+ cells were freshly
isolated from bovine PBMC using BD IMagnet Cell
Separation System (BD Biosciences, Franklin Lakes, NJ,
USA) and the following antibodies: anti-bovine CD4
mouse monoclonal antibody (mAb) (CACT138T; VMRD,
Pullman, WA, USA), anti-bovine CD8 mAb (IL-A51, a
gift from the International Livestock Research Institute,
Nairobi, Kenya), anti-bovine CD5 mAb (CACT105A,
VMRD), anti-bovine CD14 mAb (CAM36A, VMRD) or
anti-bovine CD21-like mAb (GB25A; VMRD), respect-
ively. The purity of each cell population was confirmed
with the EPICS XL flow cytometry system (Beckman
Coulter) using EPICS EXPO32 ADC software (Beckman
Coulter). Purified cells (> 90%) were used for expression
analysis by quantitative real-time PCR. cDNA was synthe-
sized from RNA samples as described above. Quantitative
RT real-time PCR was performed with a LightCycler 480
system II (Roche Diagnostics, Mannheim, Germany) using
SYBR premix DimerEraser (Takara) according to the man-
ufacturer’s instructions. Primers were 5′-GGA TCC AAT
TCC CAG GTC TAA-3′ and 5′-AGG GTC TTC AGT
GTC CGT GT-3′ for Tim-3, 5′-ACA TCC GCG CAG
CTC CCA AG-3′ and 5′-TTG ATT TGC GCC CCC
TGG GC-3′ for Gal-9, and 5′-TCT TCC AGC CTT CCT
TCC TG-3′ and 5′-ACC GTG TTG GCG TAG AGG
TC-3′ for β-actin. The cycling conditions consisted of ini-
tial denaturation at 94°C for 30 s, followed by 45 cycles of
95°C for 5 s, 60°C for 30 s and 72°C for 30 s. A final
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at a rate of 0.1°C/s (continuous acquisition), with a final
cooling to 40°C over 10 s. To estimate mRNA expression,
calibration curves were made from the measured fluores-
cence of dilution series of the control plasmid to create
the same amplification curves. Each sample was tested in
duplicate, and the results of Tim-3 and Gal-9 mRNA
expression are presented as a ratio obtained by dividing
the concentrations of Tim-3 and Gal-9 mRNA by that of
β-actin mRNA.
BLV-infected cattle
To evaluate bovine Tim-3 and Gal-9 mRNA expression
in infectious diseases, expression analyses were con-
ducted with BLV-infected cattle diagnosed at the Veter-
inary Teaching Hospital, Graduate School of Veterinary
Medicine, Hokkaido University, between 2007 and 2011.
Genomic DNA was extracted from whole blood using
the WizardTM Genomic DNA Purification kit (Promega).
BLV infection was detected by nested-PCR, and the pro-
virus load confirmed by real-time PCR as described pre-
viously [23]. Five cattle with lymphoma were diagnosed
clinically and confirmed as EBL through microscopy and
histological examinations. In other BLV-positive cattle,
the numbers of leukocytes were counted using a Celltac
α MEK-6450 automatic hematology analyzer (NIHON
KOHDEN, Tokyo, Japan), and classified as AL (n= 14)
or PL (n= 10) as described previously [23]. Ten BLV-
uninfected cattle were used as controls. To examine the
degree of immunosuppression in BLV-infected cattle,
IFN-γ and interleukin (IL)-10 mRNA expression levels
in PBMC were quantified as described previously [26].
β-actin mRNA expression was also used as an internal
control to normalize the target genes.
Generation of bovine Tim-3 expressing cells and
competitive assay
To generate Tim-3 expression vector, bovine Tim-3
cDNA was amplified as above except that primers with
restriction enzyme recognition sites, Tim-3-FLAG-F
(EcoRV): 5′-CGG CGA TAT CGC ATA TGT GTC TCA
GGT G-3′, and Tim-3-FLAG-R (NotI): 5′-ATT TGC
GGC CGC TTA GGA TTG ATG CCC ACT-3′, were
used instead. The amplified PCR product was digested
with EcoRV(Takara) and NotI (TOYOBO, Osaka, Japan),
and purified using Fast Gene Gel/PCR Exraction Kit
(Nihon genetics, Tokyo, Japan). The purified product
was ligated into the expression vector pCXN2.1-FLAG
vector [27], kindly donated by Dr Takehiko Yokomizao,
Graduate School of Medicine, Kyushu University, Fukuoka,
Japan, and transformed into a competent DH5α Escheri-
chia coli strain. The recombinant plasmid bearing Tim-3
in frame with a FLAG epitope tag was purified by
QIAGEN Plasmid Mega kit, according to the manufacturer’sprotocol (QIAGEN, Hilden, Germany), and introduced into
Cos-7 cells (African Green Monkey SV40-transformed
kidney fibroblast cell line) via transient transfection with
LipofectamineTM2000 (Invitrogen). To confirm Tim-3
expression on Cos-7 cells, western blot analysis and flow
cytometry were performed using anti-FLAG M2 mouse
monoclonal antibody (Sigma) and anti-DYKDDDDK
mouse monoclonal antibody (TransGenic, Hyogo, Japan),
respectively [28,29].
To investigate the influence of Tim-3 on cytokine pro-
duction, PBMC (8 × 106 cells) derived from BLV-infected
cattle (n= 3) and Tim-3 expressing Cos-7 (1 × 106 cells)
were co-cultured in RPMI 1640 medium (Sigma-Aldrich)
containing 10% FCS (Valley Biomedical, Winchester, VA,
USA) and 1%L-glutamine (Invirtogen) at 37°C with 5%
CO2. After 12 h, the PBMC were harvested and used to
quantify cytokine expression. Furthermore, to confirm the
synergistic effect of dual inhibitory molecule blockage, in
the same plate, Con A (5 μg/mL), anti-human pro-
grammed death-ligand 1 (PD-L1) antibody (10 μg/mL,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or IgG
isotype control rabbit antibody (Beckman Coulter) were
added to the co-cultivation set-ups at the beginning of
culture and PBMC harvested after 12 h later as described
above. To quantify cytokine mRNA expression, real-time
quantitative RT-PCR for IL-2 and IFN-γ quantification
were conducted as described previously [26].
Statistics
Two-tailed unpaired Student’s t-test and two-tailed un-
paired Welch’s t-test were used for comparison tests and
Spearman rank test was used for correlation analyses. P
values of p< 0.05 were considered significant.
Nucleotide sequence accession numbers
The sequences of the bovine Tim-3 and Gal-9 genes
have been submitted to the GenBank database under
accession number AB689695 (Tim-3) and AB689696
(Gal-9).
Results
Sequence analysis of bovine Tim-3 and its ligand
The putative amino acid sequence of bovine Tim-3
obtained from the Holstein breed is shown in Figure 1a.
The bovine Tim-3 consists of a putative signal peptide of
23 amino acids (aa), the transmembrane domain of 23 aa
and intracellular domain of 67 aa. Its extracellular domain,
consisting of 168 aa, contains an immunoglobulin domain,
the mucin domain and two potential N-linked glycosyla-
tion sites. The potential tyrosine kinase phosphorylation
motif is conserved in all mammalian Tim-3 [30]. Phylo-
genetic analysis revealed that mammalian Tim-3 was
divided into two groups, group 1 (Perissodactyla, Artio-
dactyla and Carnivora) and group 2 (Primate and
Figure 1 Bovine Tim-3. (A) Alignment of deduced amino acid sequences of Tim-3. Dots indicate identity to the sequence from Holstein breeds
and dashes indicate gaps in alignment. Two potential N-glycosylation sites are shown in bold and underlined. The potential tyrosine kinase
phosphorylation motif is indicated in the box. The accession numbers of analyzed sequences corresponded to those in Table 1. (B) A
phylogenetic tree constructed based on the amino acid sequences of Tim-3. The tree was built with the neighbor-joining method using the
MEGA 5.0 software. Numbers indicate bootstrap percentage (1000 replicates). The scale indicates the divergence time.
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tyl species group (Figure 1b). Comparative analysis of
the Tim-3 sequences of several species showed that the
bovine Tim-3 had amino acid identities of 75.8%, 74.7%,
73.3%, 69.3%, 69.0%, 62.8% and 59.9% with dog, horse,
pig, human, chimpanzee, mouse and rat, respectively(Table 1). Sequence for Gal-9 obtained from the Hol-
stein breed had an ORF encoding 356 amino acids
(Figure 2a). Bovine Gal-9 consists of an N-terminal
carbohydrate-recognition domain of 131 aa, a linker
peptide of 80 aa and a C-terminal carbohydrate-
recognition domain of 128 aa. The deduced Gal-9
Table 1 Similarity analysis of nucleic and amino acid sequences of Tim-3 among several animal species
Bos taurus (Holstein) Bos taurus (Hereford) Canis lupus familiaris Equus caballus Sus scrofa Homo sapiens Pan troglodytes Mus musculus Rattus norvegicus
(AB689695) (NM_001077105) (XM_536456) (NM_001077105) (XM_003134109) (NM_032782) (XM_518059) (NM_134250) (NM_001100762)
Bos taurus (Holstein) - 99.0 84.1 83.0 83.2 80.5 80.4 73.2 72.5
(BAL42334)
Bos taurus (Hereford) 98.9 - 84.7 83.4 83.8 80.6 80.8 73.6 73.1
(NP_001070573)
Canis lupus 75.8 76.5 - 86.6 81.1 81.8 81.7 73.0 73.6
familiaris
(XP_536456)
Equus caballus 74.7 75.1 80.1 - 82.3 83.8 83.5 73.6 75.4
(XP_003362913)
Sus scrofa 73.3 73.6 71.5 70.8 - 77.4 77.8 69.9 70.7
(XP_003134157)
Homo sapiens 69.3 69.0 71.1 73.3 65.0 - 98.3 75.0 76.6
(NP_116171)
Pan troglodytes 69.0 68.6 71.1 72.9 65.0 96.8 - 75.0 76.3
(XP_518059)
Mus musculus 62.8 62.5 62.1 60.3 54.9 65.0 65.3 - 87.6
(XP_518059)
Rattus norvegicus 59.9 60.3 63.2 61.4 56.7 65.7 66.1 81.2 -
(NP_001094232)
















Figure 2 Bovine Gal-9. Alignment of deduced amino acid sequences of Gal-9 (A) and phylogenetic tree (B) were indicated as in Figure 1. The
accession numbers of the analyzed genes corresponded to those in Table 2.
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from the dog, horse, pig, human, chimpanzee and
mouse (Table 2). The bovine Gal-9 had amino acid iden-
tities of 76.4%, 73.8%, 72.6%, 72.0%, 71.8% and 65.7% to
the pig, human, chimpanzee, dog, horse and mouse, re-
spectively. These results were further corroborated by
phylogenetic analysis (Figure 2b), with the bovine Gal-9
falling into the larger clade of the Artiodactyla order.Expression analysis of Tim-3 and its ligand during BLV
disease progression
According to several reports based on a mouse model,
Tim-3 is mainly expressed in dendritic cells (DC) and
monocytes in healthy animals [1,31]. However, Tim-3 is
upregulated in CD4+ and CD8+ T cells in LCMV and HIV
chronic infections, and acts as a negative regulator of T
cell functions [15,16]. To investigate the expression levels





Sus scrofa Homo sapiens Pan troglodytes Canis lupus
familiaris
Equus caballus Mus musculus
(AB689696) (NM_001039177) (NM_213932) (NM_009587) (XM_001156690) (HQ637390) (XM_001504079) (NM_010708)
Bos taurus (Holstein) - 99.9 85.1 82.4 82.0 81.2 80.7 73.8
(BAL42335)
Bos taurus (Hereford) 100.0 - 85.0 82.3 81.9 81.1 80.7 73.7
(NP_00103426)
Sus scrofa 76.4 76.4 - 82.8 82.2 82.2 81.1 74.8
(NP_999097)
Homo sapiens 73.8 73.8 77.2 - 95.9 82.3 81.4 77.8
(NP_033665)
Pan troglodytes 72.6 72.6 75.8 93.9 - 81.9 81.2 77.9
(XP_001156690)
Canis lupus familiaris 72.0 72.0 74.6 74.9 73.2 - 80.8 73.7
(ADR80623)
Equus caballus 71.8 71.8 71.8 71.8 71.5 72.6 - 74.8
(XP_001504129)
Mus musculus 65.7 65.7 67.4 69.5 69.2 64.8 64.3 -
(NP_034838)
Upper region shows percentages of homologies in nucleic acid level, and lower region shows those of deduced amino acid level. GenBank accession numbers are
in parentheses after species names.
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evaluated Tim-3 mRNA expression in several cell types
among PBMC isolated from BLV-infected cattle using
quantitative real-time PCR analysis (Figure 3). There wereFigure 3 Quantification of Tim-3 mRNA expression in PBMC and subp
from BLV-uninfected and BLV-infected cattle using real-rime PCR ana
mRNA. Each line indicates the mean percentages in each group. Asterisks d
and **p< 0.01).no significant differences in Tim-3 expression levels
among the cell types from BLV-free cattle. Conversely,
Tim-3 expression was significantly upregulated in PBMC
from BLV-infected cattle compared to the uninfectedopulations of CD4+, CD8+, CD5+, CD14+ and CD21+ cells derived
lysis. The concentration of Tim-3 mRNA was divided by that of β-actin
onate significant differences between the types of the cells (*p< 0.05
Figure 4 Quantitative analysis of bovine Tim-3 expression in
BLV-infected cattle at different disease stages. CD4+ (A) and
CD8+ (B) cells from BLV-negative and BLV-infected cattle with AL, PL
and lymphoma (EBL) were analyzed. Individual dots indicate Tim-3
expression level in the cells from BLV-uninfected (empty circle), AL
(full square), PL (full quarry) and lymphoma (full triangle). Each line
indicates the mean percentages in each group. Differences between
groups were considered statistically significant at probability values
of p< 0.05 (* p< 0.05; ** p< 0.01).
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in CD4+ and CD8+ T cells from infected cattle were sig-
nificantly higher than in the control group (p< 0.01). In
BLV-infected cattle, Tim-3 mRNA was mainly expressed
in CD4+ and CD8+ T cells (Figure 3), with the expression
levels in CD4+ T cells being significantly higher in aleuke-
mic (AL) (p< 0.01) and persistent lymphocytosis (PL)
(p< 0.05) cattle compared to the uninfected animals
(Figure 4a). Likewise, significant upregulation of Tim-3
mRNA was observed in CD8+ T cells from AL (p< 0.05)
and PL (p< 0.05) cattle (Figure 4b). Tim-3 expression
levels correlated positively with viral load in CD4+
(p< 0.05) and CD8+ (p< 0.01) T cells in the infected cat-
tle (Figure 5a). Furthermore, increased Tim-3 expression
levels were associated with the number of leukocytes al-
though the difference was statistically insignificant
(Figure 5b). Tim-3 expressions in CD4+ and CD8+ T cells
have a tendency to upregulate IL-10 mRNA expression
(Figure 5c).
Consequently, expression of Gal-9, the ligand for
Tim-3, was also evaluated in BLV-infected cattle. Gal-9
mRNA was mainly expressed in CD14+ cells whereas
its expression level in CD8+ T cells was significantly
higher in BLV-infected cattle than uninfected ones
(Figure 6). Significant positive correlations were noted
between Gal-9 expression in CD14+ cells and proviral
load (p< 0.01) (Figure 7a), and with the numbers of
leukocytes (p< 0.05) (Figure 7b), suggesting that Gal-9
expression increased with BLV-disease progression.
Gal-9 expression in CD14+ cells has a tendency to
down-regulate IFN-γ mRNA expression, although there
were no significant differences (Figure 7c).
Effect of the Tim-3 inhibition on cytokine expression
To confirm recombinant expression of bovine Tim-3, a
western blot assay and flow cytometric analysis were
used to determine the expression of Tim-3 on Cos-7
cells. As shown in Figure 8a, bovine Tim-3 is detected as
an approximately 29.9 kDa of a single species by West-
ern blot analysis. Moreover, flow cytometry analysis con-
firmed that bovine Tim-3 was expressed on the surface
of plasmid-transfected Cos-7 cells, with the proportion
of Tim-3+ cells being 35.8% (Figure 8b).
To investigate the cause underlying the effects of Tim-
3 on cytokine production, we examined the expression
of anti-viral cytokine (IL-2 and IFN-γ) mRNA in cul-
tured PBMC derived from BLV-infected cattle, in the
presence of bovine Tim-3 expressing cells for trapping
Tim-3 ligand, although a limited number of cattle were
tested. As shown in Figure 8c, whereas the addition of
Tim-3 expressing cells at the beginning of the 12-hr cul-
tivation period clearly augmented IFN-γ level in bovine
PBMC, the addition of mock plasmid-transfected cells
had no effect on IFN-γ expression (p< 0.05). IL-2 mRNAwas also increased by co-cultivation with the Tim-3
expressing cells, although this elevation was not statisti-
cally significant (Figure 8d). Recently, we demonstrated
the enhancement of anti-viral immune responses in vitro
Figure 5 Correlation between indicators of BLV disease progression and Tim-3 mRNA expression in BLV-infected cattle. (A) Positive
correlations were observed between proviral load (n= 23) and Tim-3 expression in CD4+ cells and CD8+ cells. (B) Correlation between the
leukocyte number and Tim-3 expression in BLV-infected cattle. (C) Correlation between IL-10 expression and Tim-3 expression in CD4+ cells was
also positive. Proviral load and IL-10 mRNA expression were determined using quantitative real-time PCR analysis. Correlation statistics were
analyzed by the Spearman rank test.
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Figure 6 Analysis of bovine Gal-9 mRNA expression in cells derived from BLV-uninfected and BLV-infected cattle. The expression analysis
was determined as in Figure 3. Each line indicates the mean percentages in each group. Asterisks donate significant differences between the
types of the cells (*p< 0.05 and **p< 0.01).
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infection [23]. Furthermore, to determine if the enhanced
response can be up-regulated by Gal-9 trapping, PBMC
from BLV-infected cattle were cultivated in the presence
of anti-PD-L1 or isotype control antibody and Tim-3
expressing cells. As shown in Figure 8e, the addition
of the Tim-3 expressing cells at the beginning of the
12-hr cultivation clearly enhanced IFN-γ expression in the
PBMC.Discussion
Recently, the cases of BLV-induced EBL and infected cat-
tle have been increasing in Japan, a worrisome trend given
that there is no effective treatment and vaccination. The
latter could be attributed to the lack of sufficient
understanding of immunological mechanisms leading to
immune evasion. During BLV-infection especially at the
PL and lymphoma stages, T-cell dysfunction characterized
by impaired cell proliferation and downregulation of Th1
cytokines accelerates disease progression through
mechanisms yet to be elucidated [26,31-34]. In the present
study, the genes for bovine Tim-3 and its ligand Gal-9,
were cloned, sequenced, and subsequently, compared with
sequences from various mammalian species. We also
demonstrated the correlation between BLV infection and
Tim-3 or Gal-9 expressions. Finally, a competitive assay
using Tim-3 expressing cells for trapping Gal-9 was con-
ducted to confirm that inhibition of Tim-3/Gal-9 pathway
could lead to up-regulation of cytokine production in
exhausted PBMC isolated from BLV-infected cattle. A
deeper understanding of the Tim-3/Gal-9 pathway in do-
mestic animals will facilitate the elucidation of eventsleading to immune dysfunction during the progression of
incurable diseases including BLV-infection.
In our studies, bovine Tim-3 expression is widely
observed in CD4+, CD5+, CD8+, CD14+ and CD21+
cells, consistent with similar findings in humans as well
as mice [1,16]. Interestingly, Tim-3 expression in PBMC
was found to be upregulated in BLV-infected cattle. In
particular, the expression levels of Tim-3 in CD4+ and
CD8+ T cells were significantly higher than those of
other cell fractions, consistent with previous reports
showing the upregulation of Tim-3 expression in
chronic human diseases [16-19]. Upregulation of Tim-3
expression on anti-viral specific CD4+ and CD8+ T cells
contributes to immune exhaustion, which results in
increased viral load and disease progression in chronic
infection with LCMV [15] and HCV [17,18]. Corres-
pondingly, bovine Tim-3 mRNA expression in CD4+
and CD8+ cells was clearly upregulated with disease
progression of BLV infection. Interestingly, Tim-3 ex-
pression levels correlated positively with viral load in
the infected cattle. In addition, Tim-3 expression levels
closely correlated with upregulation of IL-10, a negative
regulatory cytokine, as observed in a previous study
[33]. On the contrary, bovine Gal-9 is expressed in CD4
+ cells, CD8+ cells and CD14+ cells as is in humans and
mice [35,36]. The expression of Gal-9 in CD8+ T cells
was significantly higher in BLV-infected cattle than un-
infected ones. Interestingly, Gal-9 expression levels in
CD14+ cells correlated positively with two markers of
disease progression: leukocyte number and viral load.
Gal-9 acts as a ligand of Tim-3, and induces cell death in
Th1 cells but not in Th2 cells and cell death of Th1 cells
via Tim-3 [5]. In addition, a previous study showed that
Figure 7 Correlation between indicators of BLV disease
progression and Gal-9 mRNA expression in CD14+ cells from
BLV-infected cattle. Positive correlations were observed between
proviral load (A), number of leukocytes (B) and Gal-9 expression in
CD14+ cells from the infected cattle. (C) Correlation between the
IFN-γ expression and Gal-9 expression in BLV-infected cattle.
Correlation statistics were analyzed by Spearman rank test.
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ically reduced the numbers of IFN-producing Th1 cells
[5]. Furthermore, functional studies suggest that Gal-9
induces expansion of CD4+CD25+FoxP3+ regulatory T
cells and apoptosis of antigen specific CTL [20,37]. In
the present study, Gal-9 expression correlated with
downregulation of IFN-γ in the infected cattle, although
this effect was statistically insignificant. These findings
raise the possibility that the bovine Tim-3/Gal-9 path-
way is also associated with T cell exhaustion in BLV-
infection. However, Tim-3 expression levels did not cor-
relate with downregulation of IFN-γ in contrast with
our previous data [23], suggesting up-regulation of PD-
L1 in BLV infected cattle (data not shown). In addition,
the mechanism behind upregulation of Tim-3 and Gal-9
is still unclear. Further studies are necessary to deter-
mine the correlation between Tim-3 expression and T
cell dysfunction in infected cattle.
Although the role of Tim-3/Gal-9 pathway in the
immunosuppression of the BLV-infection is still specula-
tive, the over-expression of Tim-3 and Gal-9 is apparently
involved in T-cell dysfunctions during chronic disease
progression in human and animal models. Recently, the
blocking of Tim-3/Gal-9 pathway with an antibody spe-
cific to Tim-3 was shown to restore T cell function during
HCV infection in vitro [18]. Moreover, in the cases of
LCMV, HIV infection and cancer, Tim-3 and PD-1 are co-
expressed by exhausted CD8+ T-cells, and dual blockade
of Tim-3 and PD-L1 enhances T-cell responses as well as
controlling virus and tumor [15,16,19,38]. These observa-
tions collectively indicate that Tim-3 blockade could be a
potential treatment for chronic diseases. However, no
functional analysis of these molecules has been reported
for cattle and bovine diseases, primarily due to the lack of
specific antibodies. Thus, we also investigated the effects
of inhibiting the Tim-3/Gal-9 pathway. Predictably, inhib-
ition of the Tim-3/Gal-9 pathway in vitro by Tim-3
expressing cells upregulated the production of IL-2 and
IFN-γ. Moreover, combined blockade of PD-L1 and
Tim-3 acted in synergy to enhance IFN-γ induction in
exhausted cells from BLV-infected cattle. More interest-
ingly, the magnitude to restore cytokine induction was
dependent on Tim-3 and Gal-9 expression levels, al-
though a limited number of animals were tested (data not




















































































































Figure 8 Inhibition of the Tim-3/Gal-9 pathway increases cytokine expression in PBMC from BLV-infected cattle. (A and B) The
expression of bovine Tim-3 on Cos7 cells. The detections were performed by (A) Western blotting analysis and (B) Flowcytometric analysis with
anti-FLAG antibody as described elsewhere. Empty plasmid-transfected cells were used as mock for each assay. (C, D and E) Real-time PCR
quantification of mRNA expression levels for cytokines in the treated-PBMC from BLV-infected cattle (n= 3). Up-regulations of IL-2 (C) and IFN-γ
(D) expressions in PBMC by the inhibition of the Tim-3/Gal-9 pathway using Tim-3 expressing cells (Tim-3-FLAG). Up-regulations of IFN-γ (E)
expressions by blockade of the PD-1/PD-L1 pathway using anti-PD-L1 antibody (α-PD-L1) and enhancement of the expression by combination
PD-L1 blockade with Tim-3 expressing cells. Each cytokine mRNA level was normalized by the bovine β-actin mRNA as above, and the relative
index was determined in comparison to the cytokine mRNA level in the PBMC without Tim-3 expressing cells and antibodies. The results are
means of three independent experiments using cells from three individual cattle. Asterisks donate significant differences between the types of
the cells (*p< 0.05).
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http://www.veterinaryresearch.org/content/43/1/45bindings between Gal-9 derived from the test animals
and Tim-3 expressed on transfected cells, might sug-
gest that Tim-3 is involved in the inhibition of T-cell
function in BLV infection.In conclusion, the Tim-3/Gal-9 pathway might link dis-
ease progression with T cell exhaustion during BLV infec-
tion. Further investigations are required to develop a
novel vaccine or therapeutic method against BLV
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combinant Tim-3 Fc fusion protein.
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